ChongKunDang’s arthritis treatment gets approval for clinical trials in Netherlands
Aug 9, 2016
[THE INVESTOR] ChongKunDang’s pharmaceutical composition CKD-506 has been approved by Netherland’s Central Committee on Research Involving Human Subjects (CCMO) for phase 1 clinical trials, it announced on Aug. 9.The preclinical candidate is for the treatment of autoimmune diseases by selectively inhibiting HDAC6 that can affect a variety of inflammatory diseases. It represses inflammation and enhances T cell function that tailors immune responses, and has been found to be effective for rheumato